贝伐珠单抗联合辅助化疗治疗淋巴结阳性及高危淋巴结阴性乳腺癌的双盲III期试验(E5103)
E5103研究在HER2阴性高危乳腺癌患者中评估辅助化疗联合贝伐珠单抗的疗效。结果显示,联合贝伐珠单抗并未改善无浸润性疾病生存(IDFS)或总生存,且贝伐珠单抗早期停药率高。
要点
- 贝伐珠单抗联合辅助化疗未改善HER2阴性高危乳腺癌的IDFS或OS。
- 贝伐珠单抗组≥3级高血压更常见,但血栓、蛋白尿和出血无差异。
- 贝伐珠单抗早期停药率高,延长治疗可行性低。
核心结论
- 在HER2阴性高危乳腺癌患者中,将贝伐珠单抗纳入序贯蒽环类和紫杉类辅助化疗并未改善无浸润性疾病生存(IDFS)或总生存(OS)。
- 鉴于早期停药率高,更长时间的贝伐珠单抗治疗不太可能可行。
研究设计与样本
- 患者按1:2:2随机分配至A组(安慰剂+多柔比星/环磷酰胺序贯紫杉醇)、B组(贝伐珠单抗仅 during AC和紫杉醇)、C组(贝伐珠单抗 during AC和紫杉醇后贝伐珠单抗单药维持10周期)。
- 主要终点为无浸润性疾病生存(IDFS)。
主要发现
- 中位年龄52岁;64%雌激素受体阳性,27%淋巴结阴性,78%接受剂量密集AC方案。
- 化疗相关不良事件(包括骨髓抑制和神经病变)在各组间相似。
- 贝伐珠单抗治疗组≥3级高血压更常见,但血栓形成、蛋白尿和出血无差异。
- 15个月时临床充血性心力衰竭累积发生率在A、B、C组分别为1.0%、1.9%、3.0%。
- 5年IDFS在A组为77%(95% CI,71%至81%),B组为76%(95% CI,72%至80%),C组为80%(95% CI,77%至83%)。
关键数值与推荐
- 5年IDFS:A组77%(95% CI,71%至81%),B组76%(95% CI,72%至80%),C组80%(95% CI,77%至83%)。
- 15个月临床充血性心力衰竭累积发生率:A组1.0%,B组1.9%,C组3.0%。
- 贝伐珠单抗早期停药率:B组约24%,C组约55%未完成计划治疗。
临床怎么用
- 不推荐在HER2阴性高危乳腺癌的辅助化疗中常规加入贝伐珠单抗。
- 贝伐珠单抗联合辅助化疗时需监测高血压和心功能,但未能改善生存。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Purpose Bevacizumab improves progression-free survival but not overall survival in patients with metastatic breast cancer. E5103 tested the effect of bevacizumab in the adjuvant setting in patients with human epidermal growth factor receptor 2-negative disease. Patients and Methods Patients were assigned 1:2:2 to receive placebo with doxorubicin and cyclophosphamide (AC) followed by weekly paclitaxel (arm A), bevacizumab only during AC and paclitaxel (arm B), or bevacizumab during AC and paclitaxel followed by bevacizumab monotherapy for 10 cycles (arm C). Random assignment was stratified and bevacizumab dose adjusted for choice of AC schedule. Radiation and hormonal therapy were administered concurrently with bevacizumab in arm C. The primary end point was invasive disease-free survival (IDFS). Results Four thousand nine hundred ninety-four patients were enrolled. Median age was 52 years; 64% of patients were estrogen receptor positive, 27% were lymph node negative, and 78% received dose-dense AC. Chemotherapy-associated adverse events including myelosuppression and neuropathy were similar across all arms. Grade ≥ 3 hypertension was more common in bevacizumab-treated patients, but thrombosis, proteinuria, and hemorrhage were not. The cumulative incidence of clinical congestive heart failure at 15 months was 1.0%, 1.9%, and 3.0% in arms A, B, and C, respectively. Bevacizumab exposure was less than anticipated, with approximately 24% of patients in arm B and approximately 55% of patients in arm C discontinuing bevacizumab before completing planned therapy. Five-year IDFS was 77% (95% CI, 71% to 81%) in arm A, 76% (95% CI, 72% to 80%) in arm B, and 80% (95% CI, 77% to 83%) in arm C. Conclusion Incorporation of bevacizumab into sequential anthracycline- and taxane-containing adjuvant therapy does not improve IDFS or overall survival in patients with high-risk human epidermal growth factor receptor 2-negative breast cancer. Longer duration bevacizumab therapy is unlikely to be feasible given the high rate of early discontinuation.
引用
- Miller KD, O'Neill A, Gradishar W, et al. Double-Blind Phase III Trial of Adjuvant Chemotherapy With and Without Bevacizumab in Patients With Lymph Node-Positive and High-Risk Lymph Node-Negative Breast Cancer (E5103). J Clin Oncol. 2018. PMID: 30040523. doi:10.1200/JCO.2018.79.2028
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。